The role of Epigenetics in Kidney malignancies

Central European Journal of Urology

Volumn 68, Issue 2, 2015, Pages 157-164

  Harb De la Rosa, Alfredo ^a   Acker, Matthew ^a   Swain, Sanjaya ^a   Manoharan, Murugesan ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

DNA methylation; Histone modification; Kidney cancer; MicroRNA regulation

Indexed keywords

ABEXINOSTAT; AQUAPORIN 1; AR 42; AZACITIDINE; BORTEZOMIB; CISPLATIN; DC 05; DC 501; DC 517; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; LY 2409881; MG 98; MICRORNA; RICOLINOSTAT; ROMIDEPSIN; UNCLASSIFIED DRUG; VORINOSTAT;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MUTATION; REVIEW; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 84931828331     PISSN: 20804806     EISSN: 20804873     Source Type: Journal    
DOI: 10.5173/ceju.2015.453     Document Type: Review

References (58)

1. Henrique R, Luís AS, Jerónimo C. The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet. 2012; 3: 94.
2. Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol. 2010; 4: 58-73.
3. Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. Biomarkers in renal cancer. Virchows Arch. 2014; 464: 359-365.
4. Slater AA, Alokail M, Gentle D, Yao M, Kovacs G, Maher ER, Latif F. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics. 2013; 8: 252-267.
5. van der Heijden AG. The role of methylation in urological tumours. Arch Esp Urol. 2013; 66: 432-439.
6. Whayne TF. Epigenetics in the development, modification, and prevention of cardiovascular disease. Mol Biol Rep. 2014; 42: 765-776.
7. Schiffgen M, Schmidt DH, von Rücker A, Müller SC, Ellinger J. Epigenetic regulation of microRNA expression in renal cell carcinoma. Biochem Biophys Res Commun. 2013; 436: 79-84.
8. Grange C, Collino F, Tapparo M, Camussi G. Oncogenic micro-RNAs and Renal Cell Carcinoma. Front Oncol. 2014; 4: 49.
9. Hauser S, Zahalka T, Fechner G, Müller SC, Ellinger J. Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res. 2013; 33: 4651-4656.
10. Das PM, Singal R. Singal. DNA methylation and cancer. J Clin Oncol. 2004; 22: 4632-4642.
11. Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T. Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues. Pathobiology. 2011; 78: 1-9.
12. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Epigenetics in prostate cancer. Prostate Cancer. 2011 doi: 10.1155/2011/580318
13. Ellinger J, Holl D, Nuhn P, Kahl P, Haseke N, Staehler M, et al. DNA hypermethylation in papillary renal cell carcinoma. BJU Int. 2011; 107: 664-669.
14. Ricketts CJ, Hill VK, Linehan WM. Linehan. Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One. 2014; 9: e85621.
15. Manoharan M, Ramachandran K, Soloway MS, Singal R. Epigenetic targets in the diagnosis and treatment of prostate cancer. Int Braz J Urol. 2007; 33: 11-18.
16. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 2003; 63: 8695-8659.
17. Woo HD, Kim J. Global DNA hypomethylation in peripheral blood leukocytes as a biomarker for cancer risk: a meta-analysis. PLoS One. 2012; 7: e34615.
18. Ludgate JL, Le Mée G, Fukuzawa R, Rodger EJ, Weeks RJ, Reeve AE, Morison IM. Global demethylation in loss of imprinting subtype of Wilms tumor. Genes Chromosomes Cancer. 2013; 52: 174-184.
19. Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H, Hofstra RM, Kok K. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 2010; 70: 4287-4291.
20. Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J. 2013; 19: 333-340.
21. Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, et al, MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther. 2014; 15: 329-341.
22. Chen X, Ruan A, Wang X, Han W, Wang R, Lou N, et al. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes. J Cancer Res Clin Oncol. 2014; 140: 1295-1304.
23. Huang J, Yao X, Zhang J, Dong B, Chen Q, Xue W et al. Hypoxia-induced downregulation of miR-30c promotes epithelial-mesenchymal transition in human renal cell carcinoma. Cancer Sci. 2013; 104: 1609-1617.
24. Liberko M, Kolostova K, Bobek V. Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol. 2013; 88: 338-356.
25. Ahmed FE. Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn. 2007; 7: 569-603.
26. Coppolino G, Bolignano D, Rivoli L, Mazza G, Presta P, Fuiano G. Tumour markers and kidney function: a systematic review. Biomed Res Int. 2014; doi: 10.1155/2014/647541
27. Lucarelli G, Ditonno P, Bettocchi C, Vavallo A, Rutigliano M, Galleggiante V, et al. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers. 2014; doi: 10.1155/2014/689795
28. Gerashchenko GV, Bogatyrova OO, Rudenko EE, Kondratov AG, Gordiyuk VV, Zgonnyk YM, et al. Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas. Exp Oncol. 2010; 32: 71-75.
29. Eggers H, Steffens S, Grosshennig A, Becker JU, Hennenlotter J, Stenzl A, et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. Int J Oncol. 2012; 40: 1650-1658.
30. Patrício P, Ramalho-Carvalho J, Costa- -Pinheiro P, Almeida M, Barros-Silva JD, Vieira J, et al. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis. J Cell Mol Med. 2013; 17: 1048-1058.
31. Xiao W, Wang J, Li H, Guan W, Xia D, Yu G, et al. Fibulin-1 is down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression. J Urol. 2013; 190: 291-301.
32. Guan R, Qiu W, Xin D, Gingrich JR, Guo Y, Chang G, et al. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun. 2013; 435: 526-532.
33. Selvakumar P, Owens TA, David JM, Petrelli NJ, Christensen BC, Lakshmikuttyamma A, Rajasekaran AK. Epigenetic silencing of Na, K-ATPase beta 1 subunit gene ATP1B1 by methylation in clear cell renal cell carcinoma. Epigenetics. 2014; 9: 579-586.
34. Morrissey JJ, Mobley J, Song J, Vetter J, Luo J, Bhayani S, et al. Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade. Urology. 2014; 83: 256 e9-14.
35. Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013; 108: 131-138.
36. Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Int J Oncol. 2014; 44: 53-58.
37. Zhao J, Lei T, Xu C, Li H, Ma W, Yang Y, Fan S, Liu Y. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. Biochem Biophys Res Commun. 2013; 438: 439-444.
38. Jayaraj GG, Nahar S, Maiti S. Nonconventional chemical inhibitors of microRNA: therapeutic scope. Chem Commun (Camb). 2014; 51: 820-831.
39. O'Rourke CJ, Knabben V, Bolton E, Moran D, Lynch T, Hollywood D, Perry AS. Manipulating the epigenome for the treatment of urological malignancies. Pharmacol Ther. 2013; 138: 185-196.
40. Amato RJ, Stephenson J, Hotte S, Nemunaitis J, Bélanger K, Reid G, Martell RE. MG98, a second-generation DNMT1 inhibitor, in the treatment of advanced renal cell carcinoma. Cancer Invest. 2012; 30: 415-521.
41. Konac E, Varol N, Yilmaz A, Menevse S, Sozen S. DNA methyltransferase inhibitor-mediated apoptosis in the Wnt/ beta-catenin signal pathway in a renal cell carcinoma cell line. Exp Biol Med (Maywood). 2013; 23: 1009-1016.
42. Yamada T, Horinaka M, Shinnoh M, Yoshioka T, Miki T, Sakai T. A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma. Int J Oncol. 2013; 43: 1080-1086.
43. Juengel E, Makarević J, Tsaur I, Bartsch G, Nelson K, Haferkamp A, Blaheta RA. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One. 2013; 8: e53100.
44. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014; 5: 265-296.
45. Ahmad ST, Arjumand W, Seth A, Saini AK, Sultana S. Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol. 2012; 33: 395-402.
46. Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER, et al., Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001; 61: 7277-7281.
47. Hoffman AM, Cairns P. Epigenetics of kidney cancer and bladder cancer. Epigenomics. 2011; 3: 19-34.
48. Chalret du Rieu Q, Fouliard S, White- Koning M, Kloos I, Chatelut E, Chenel M. Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients. Invest New Drugs. 2014; 32: 985-994.
49. Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, et al. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther. 2014; 13: 1979-1990.
50. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012; 119: 2579-2589.
51. Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res. 2013; 19: 4499-44507.
52. Kurundkar D, Srivastava RK, Chaudhary SC, Ballestas ME, Kopelovich L, Elmets CA, Athar M. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model. Toxicol Appl Pharmacol. 2013; 266: 233-244.
53. Qi YF, Huang YX, Dong Y, Zheng LH, Bao YL, Sun LG, et al. Systematic analysis of time- -series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors. Comput Math Methods Med. 2014; doi: 10.1155/2014/867289
54. Deng C, Lipstein M, Rodriguez R, Serrano XO, McIntosh C, Tsai WY, et al. The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-kB. Clin Cancer Res. 2014; 21: 134-145.
55. Chen S, Wang Y, Zhou W, Li S, Peng J, Shi Z, et al. Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors through Docking-Based Virtual Screening. J Med Chem. 2014; doi: 10.1021/jm501134e
56. Fandy TE, Jiemjit A, Thakar M, Rhoden P, Suarez L, Gore SD. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. Clin Cancer Res. 2014; 20: 1249-1258.
57. Winquist E, Knox J, Ayoub JP, Wood L, Wainman N, Reid GK, et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs. 2006; 24: 159-167.
58. Tikoo K, Ali IY, Gupta J, Gupta C. 5-Azacytidine prevents cisplatin induced nephrotoxicity and potentiates anticancer activity of cisplatin by involving inhibition of metallothionein, pAKT and DNMT1 expression in chemical induced cancer rats. Toxicol Lett. 2009; 191: 158-166.